Case Study



The company

  • Region: Europe
  • Sector: Industrials
  • Stage: Small/mid buyout
  • Type: Primary
  • Fund Vintage: 2017
  • Exit Type: Trade Sale
  • Highlights:

Private Equity Manager (GP)

Case study

About the company

Biolchim specialises in the production and commercialisation of bio-stimulants and specialty fertilisers. These enable farmers to improve the quantity and quality of their crops while using less water and chemical fertilisers.


Investment rationale

  • Biolchim is a producer of environmentally-friendly bio-stimulants, made mostly from raw materials of natural origin.
  • Potential to improve product mix and focus on highly specialised products.
  • Opportunity for further international expansion, both organically and through acquisitions.

Our relationship

PIP is a primary investor in three Chequers Capital funds and Pantheon holds an advisory board seat for each fund. In addition, PIP has previously co-invested alongside Chequers Capital.

Active management and value creation

  • Increased the quality of the business by improving the efficacy of the products, building a larger portfolio, strong research and development, and better financial performance.
  • Increased awareness among fertiliser manufacturers of the need to offer greener products.
  • International expansion to over 50 countries with production facilities in Europe and South America.
  • Strong performance across subsidiaries in China, Brazil, Hungary and Italy.
  • Pricing power, with the ability to re-price products and services in an inflationary environment.
  • Successful management of the operations and supply chain resulting in EBITDA, growth including during a period of increasing raw materials prices and energy costs.
  • Biolchim achieved a three-year earnings revenue CAGR of 8% and three-year earnings CAGR of 14%.
  • A large strategic multiple uplift accounts for most of the value creation and was achieved through positioning the company to be an attractive acquisition target for a large trade buyer.


Biolchim was acquired by US strategic corporation buyer, J.M. Huber, in November 2022 after a competitive selling process with several trade buyers took place. This provided a full exit for Chequers Capital and for PIP at a Multiple of Invested Cost (MOIC) of 4.2x and IRR of 36%. The uplift versus the December 2021 valuation was 40%.

Back to case studies

You may also like

Our portfolio

Actively managed for our shareholders

PIP's global, diversified portfolio gives exposure to many high quality managers, sectors and companies.

Find out more

Our investment process

Decades of experience, expertise and deep relationships

We have a rigorous and detailed approach to selecting our private equity managers and assessing deals.

Find out more